Skip to content

GSK’s RSV Vaccine Approved By FDA For High-Risk Adults in Expanded Age Range

Sam Boughedda trader
Updated 10 Jun 2024

GSK's (LON: GSK) RSV vaccine, Arexvy, has been approved by the FDA for use in adults aged 50-59 who are at increased risk of severe RSV outcomes, the company said late Friday.

GSK Office

YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.


This expands the age range for the vaccine, which was previously only approved for adults 60 and older.

This age group includes over 13 million adults in the US with underlying medical conditions like COPD, asthma, heart failure, and diabetes. These conditions can increase the risk of serious complications from RSV infection.

GSK's approval for the expanded age range was supported by a Phase 3 trial showing the vaccine's safety and effectiveness in adults aged 50-59, including those with high-risk conditions.

GSK is also seeking approval for this age group in Europe, Japan, and other countries. The company adds that trials to evaluate the vaccine in younger adults (18-49) and immunocompromised adults are ongoing, with results expected later in 2024.

Tony Wood, Chief Scientific Officer at GSK, said: “Today's approval reflects the importance of broadening the benefits of RSV immunisation to adults aged 50-59 who are at increased risk.

“For those with underlying medical conditions, RSV can have serious consequences, so we are proud to be the first to help protect them from RSV-LRTD.”

Last week, GSK shares plunged more than 9% after a Delaware judge ruled on May 31 that over 72,000 lawsuits regarding discontinued heartburn drug Zantac could go ahead.

Despite the decline, the stock is still up more than 11% this year, trading around the 1,629p mark.

Searching for the Perfect Broker?

Discover our top-recommended brokers for trading stocks, forex, cryptos, and beyond. Dive in and test their capabilities with complimentary demo accounts today!

YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY


YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.


Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples.